Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. - Wikidata - wikimedia - TriplyDB

Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16.

Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16.

http://www.wikidata.org/entity/Q40333321

about

Prostate cancer treatment: the times they are a' changin'Chemotherapy research for metastatic prostate cancer Role of Chemotherapy and Mechanisms of Resistance to Chemotherapy in Metastatic Castration-Resistant Prostate Cancer Chemotherapy options in castration-resistant prostate cancer Semiparametric inference for surrogate endpoints with bivariate censored data.Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer.Targeting DNA repair with combination veliparib (ABT-888) and temozolomide in patients with metastatic castration-resistant prostate cancer Docetaxel plus oral metronomic cyclophosphamide: a phase II study with pharmacodynamic and pharmacogenetic analyses in castration-resistant prostate cancer patients.Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916 An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223 Serum/glucocorticoid-regulated kinase 1 expression in primary human prostate cancers.Circulating tumor cells in prostate cancer diagnosis and monitoring: an appraisal of clinical potential.COOPERATIVE GROUP TRIALS - SOUTHWEST ONCOLOGY GROUP (SWOG) INNOVATIONS IN ADVANCED PROSTATE CANCER.End points of clinical trials in metastatic castration-resistant prostate cancer: A systematic review Identification of a novel prostate cancer biomarker, caveolin-1: Implications and potential clinical benefit.A phase 2 clinical trial of everolimus plus bicalutamide for castration-resistant prostate cancer.Potential utility of cancer-specific biomarkers for assessing response to hormonal treatments in metastatic prostate cancer.BMI1, stem cell factor acting as novel serum-biomarker for Caucasian and African-American prostate cancer.Sequential use of the androgen synthesis inhibitors ketoconazole and abiraterone acetate in castration-resistant prostate cancer and the predictive value of circulating androgens.Tolerability, safety and pharmacokinetics of ridaforolimus in combination with bicalutamide in patients with asymptomatic, metastatic castration-resistant prostate cancer (CRPC).Change in PSA velocity is a predictor of overall survival in men with biochemically-recurrent prostate cancer treated with nonhormonal agents: combined analysis of four phase-2 trials.A phase II trial of personalized peptide vaccination in castration-resistant prostate cancer patients: prolongation of prostate-specific antigen doubling time.Comparison of active and passive targeting of docetaxel for prostate cancer therapy by HPMA copolymer-RGDfK conjugates.A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study.Changes in PSA kinetics predict metastasis- free survival in men with PSA-recurrent prostate cancer treated with nonhormonal agents: combined analysis of 4 phase II trials Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer Sexual, irritative, and voiding outcomes, following stereotactic body radiation therapy for prostate cancer.Challenges to improved therapeutics for metastatic castrate resistant prostate cancer: from recent successes and failures.Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer.The association between radiographic response and overall survival in men with metastatic castration-resistant prostate cancer receiving chemotherapy.Evaluating the value of number of cycles of docetaxel and prednisone in men with metastatic castration-resistant prostate cancer.Biomarkers for the Management of Castration-Resistant Prostate Cancer: We Are Not There Yet.Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer Very Early PSA Response to Abiraterone in mCRPC Patients: A Novel Prognostic Factor Predicting Overall Survival Update in systemic therapy of prostate cancer: improvement in quality and duration of life.Evolving perspectives of the role of novel agents in androgen-independent prostate cancer.Progression-free survival as a predictor of overall survival in men with castrate-resistant prostate cancer.Prostate-specific antigen changes as surrogate for overall survival in men with metastatic castration-resistant prostate cancer treated with second-line chemotherapy Prostate-specific antigen response rate of sequential chemotherapy in castration-resistant prostate cancer: the results of real life practice.Potential surrogate endpoints for prostate cancer survival: analysis of a phase III randomized trial.

P2860

Q27025607-155C95AE-44B5-4582-9364-102DC61F1647 Q28071468-4C9FAA38-B1FA-48B0-B07F-71D9FD7D38B8 Q28075965-5E53F214-27DB-4613-B96B-31A28B6BD423 Q28078477-E8DE2C97-1FF9-4E2B-A62D-32E70CFAD199 Q31119657-1D5CCBA9-A0A7-437F-ABF6-4773A7EE97CB Q33408024-DD63E6DE-833F-48E9-A605-E81074972E8D Q33414863-4F5880CB-9A3F-4F1D-9389-1B07CB41A985 Q33416977-42AB9EAF-D3FB-4740-AA99-A35708D80D7A Q33432475-C68B8F82-A47D-4AC7-8D57-C58AABC797CE Q33608134-7D1375B6-8029-46C3-9108-40C7EAC931B8 Q33896203-EF850509-011A-4BFB-B440-FF00F992790E Q34108738-A5414963-A809-4959-A499-2AB0E55BAF40 Q34309132-DC22DB68-77FE-437A-8C02-D683B86DA45E Q34367585-8B11006D-EB71-4EE3-8FA6-EE5E7DB68209 Q34417941-D0C0D92C-5C20-4EE9-BEF9-AC6288DE4CC0 Q34520021-50A6E4C2-736A-41FA-9E54-1F0B34E1354D Q34536729-D7EEB876-F8DC-4534-AE03-4FE46BC6F666 Q34544617-DFAE8230-440A-4CC3-B6CD-7C968FBD3AF0 Q34778772-ECE28830-AEFF-4F70-AA7D-ABBDCF49511B Q34900827-5C2CACBB-F4BE-4E04-A990-2D69B2853AF6 Q35070443-3663126E-76D6-437A-96C4-6CE986293EF5 Q35076925-D27DC043-BC63-4401-992C-A9C114740675 Q35227265-3FD5D1DD-C240-448B-9F0D-8B3B5DED448E Q35576853-CB0AD376-4556-463F-AEA3-32C5E233CE3E Q35656240-8224626B-DC2E-48CB-B862-65FBF03F2FF1 Q35967139-3F28E09D-FDF2-41B8-8764-82E00F0035B9 Q36009944-EA2956A4-8F16-4476-A25A-F15909CDB7FB Q36181578-D65E3011-60F9-4764-937B-91E0A56B5A4C Q36243296-D004E113-6B57-4599-9079-B18EF0D07786 Q36353287-5D00EC5E-5CEE-4D1F-AD78-4D52A5EE7280 Q36353291-05ADE151-EB1A-4D2C-ABEA-725204EBAFB2 Q36407003-01BFBC6B-FA82-4FF5-947B-EB592A506FC4 Q36504117-DA9F2152-65C1-4B8D-ABC7-E1D7D86DB2E7 Q36909750-695E7027-4CB8-47F3-9F67-AA67C8809487 Q37086017-DE8BBB23-7D8B-4BD6-91FB-98C6416278D4 Q37197722-F71C7613-EEE7-4A22-816C-477A6B4DD816 Q37231510-A029A683-C311-4277-9B97-CEA651C3CBD4 Q37249358-BC6E7BE1-EF6F-4E3F-8D09-08929600DC06 Q37270491-5DEAFF7F-CD7C-4EF8-9BDC-C041FB6BD71A Q37324245-298D2B1C-80FA-4B4D-B2E9-7BFD8C16CAAB

P2860

Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16.

http://www.wikidata.org/entity/Q40333321

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

2006年论文

@zh

2006年论文

@zh-cn

name

Evaluation of prostate-specifi ...... atients treated on SWOG 99-16.

@en

type

label

Evaluation of prostate-specifi ...... atients treated on SWOG 99-16.

@en

prefLabel

Evaluation of prostate-specifi ...... atients treated on SWOG 99-16.

@en

P1433

Q40333321-9CA3FCCF-C7E6-4D3C-8DE1-3C0E14460451

P1476

Q40333321-D15307C5-A4FC-453A-9E02-8D7FC878248A

P2093

Q40333321-17404E5E-D832-4F59-9454-E8241902EA88

Q40333321-34018CDF-96F5-4654-B8FC-683FFF486FA9

Q40333321-3AB4CCA4-F84A-45E6-B1A9-0446F36632C9

Q40333321-40CA7FE5-A409-4CA9-AAF3-045D1DA80441

Q40333321-581209F5-0A2F-4D96-9577-75E1A1F1C653

Q40333321-8581642A-5E91-4EDF-9798-825084D5CE9D

Q40333321-9479FF79-0C77-492E-8688-159350FCD2F9

Q40333321-9A7F8589-EAED-4644-84A4-E592F0C3EB1B

Q40333321-B4EFFA2B-38A3-46FF-8A94-AFC0E794DFBF

Q40333321-C19C9094-4F9F-4CA7-9F14-55E94F5C33E4

P304

Q40333321-BD9EBD3C-B678-458C-BF9B-CC7E3969E3B1

P31

Q40333321-EF07602A-1BDA-4190-B94D-B0DB33916B20

P356

Q40333321-438779E2-3A6F-4374-8074-8DDE4E3DDD86

P407

Q40333321-790C7450-61DA-48DD-8FEA-18117B341789

P433

Q40333321-12D7FC43-5A92-491D-A72E-F3F4A043301A

P478

Q40333321-83BAE7D4-9DA5-4A31-ACF7-481E42C75A30

P50

Q40333321-062C60F4-8345-4D7A-9565-2EF784ED58F8

Q40333321-A901723E-41B0-4740-AB60-5F27F5CEACEE

P577

Q40333321-B47DAB2D-0978-4BD0-AAB5-572FE91D935F

P5875

Q40333321-4B25C2A2-E648-414C-85CF-29E45A8C0401

P698

Q40333321-4D9F434A-7B8C-446D-A29F-09A1FACEDD27

P356

P1433

Journal of the National Cancer Institute

P1476

Evaluation of prostate-specifi ...... atients treated on SWOG 99-16.

@en

P2093

Caroline S Jiang

http://www.w3.org/2001/XMLSchema#string

Catherine M Tangen

http://www.w3.org/2001/XMLSchema#string

Daniel P Petrylak

http://www.w3.org/2001/XMLSchema#string

Derek Raghavan

http://www.w3.org/2001/XMLSchema#string

E David Crawford

http://www.w3.org/2001/XMLSchema#string

Eric J Small

http://www.w3.org/2001/XMLSchema#string

Jeffrey A Jones

http://www.w3.org/2001/XMLSchema#string

Maha H A Hussain

http://www.w3.org/2001/XMLSchema#string

Manish Kohli

http://www.w3.org/2001/XMLSchema#string

Mitchell C Benson

http://www.w3.org/2001/XMLSchema#string

P304

516-521

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/JNCI/DJJ129

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

98

http://www.w3.org/2001/XMLSchema#string

P50

Mary-Ellen Taplin

P577

2006-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7158441

http://www.w3.org/2001/XMLSchema#string

P698

16622120

http://www.w3.org/2001/XMLSchema#string